Image
Image

Cytotoxic and High-Potency Manufacturing

30+ years of dedicated cytotoxic manufacturing expertise. A purpose-built oncology facility. Regulatory credentials to supply the world's most demanding markets.

What Sets Us Apart

Dedicated Oncology Environment

A self-contained facility built specifically for cytotoxic programs, with its own laboratories, manufacturing environment, and quality systems from day one.
Image

01

Containment Systems

Restricted Access Barrier System (RABS) filling restricts access to the critical filling zone, providing full operator and product protection.
Image

02

Decades of Experience

A long-tenured specialist team with deep institutional expertise, built through decades of uninterrupted cytotoxic manufacturing.
Image

03

Every Chemotherapy Classes

Commercial manufacturing experience across anthracyclines, platinum-based chemotherapies, taxanes, topoisomerase inhibitors, antimetabolites, and vinca alkaloids.
Image

04

    From First Batch to Commercial Supply

    Image

    Feasibility and Technology Transfer

    Compound-specific feasibility assessment and containment level review. Technology transfer with cleaning validation and containment verification.
    Image

    Clinical to Commercial

    Clinical-scale GMP batch manufacture under RABS containment through to commercial scale-up, stability management, and multi-SKU portfolio management for late-lifecycle programs.
    Image

    Global Regulatory Alignment

    CMC documentation and regulatory submission support for IND, CTN, NCE, and commercial applications. QC release and distribution to 70+ countries across FDA, EMA, TGA, and ANVISA markets.

    What We Can Handle

    Image

    Containment Classification

    RABS containment rated to OEB5, with an OEL below 1 µg/m³. Designed for cytotoxic, high-potency, and highly active compounds requiring the highest level of operator and product protection.
    Image

    High-Potency Products Manufactured

    Oncology classes manufactured include anthracyclines, platinum-based chemotherapies, taxanes, vinca alkaloids, antimetabolites, and topoisomerase inhibitors, across clinical and commercial programs.

    Did you know manufacturing in Australia could fund nearly half your program?

    Learn More
    Image

    Drug Product Manufacturing Track Record

    0+ years
    of Sterile Manufacturing Heritage
    0M+ units
    Annual Capacity
    Image
    Image
    0+
    Approved Products
    0+
    Countries Delivered
    Image

    Ready to Scale Your Oncology Program?

    Our team is ready to discuss your cytotoxic manufacturing needs.